Board

Ron H.N. van Schaik (President)

2014 OR-21

Ron H.N. van Schaik, PhD is a registered European Clinical Chemist (2003) and Full Professor Pharmacogenetics (2013). He is working at the department of Clinical Chemistry (AKC) at the Erasmus University Medical Center (Erasmus MC) in Rotterdam since 1998. He studied chemistry at Utrecht University (specializations Biochemistry, Clinical Chemistry and Molecular Biology) and received his PhD in 1992. He was trained in molecular biology at Cold Spring Harbor Laboratories in New York. From 1992, he worked as post-doc at the Erasmus University (Dept. Endocrinology & Reproduction) and the Academic Hospital Rotterdam (Dept. Pathology, Dept. Clinical Chemistry) on translational research involving molecular biological testing. Currently, he is medical coordinator of the AKC units Specialized Research & Development (BO&O). He is Director of the National and International (IFCC) Expert Center Pharmacogenetics.  

Prof. van Schaik leads a research group on pharmacogenetics, in which the translation to implementation for patient diagnostics is the main topic. Current lines of research include Transplantation/immunosuppression, Oncology, Psychiatry, Anaesthesiology, Pain and Virology. He has published over 180 articles on pharmacogenetics (H-factor 46), and he participates in national (NVKC, KNMP) and international (IFCC, AACC, IATDMCT, EUSPM, Genomic Medicine Alliance, European Medicine Agency) advisory committees on this topic. As a second line of research, he is involved in studies on new markers for the detection of prostate cancer. In 2001, Dr. van Schaik received the Ortho Clinical Diagnostics Award of the Dutch Society for Clinical Chemistry for outstanding research. In 2008, the Pharmacogenetics Core Laboratory AKC got internationally recognized by the International Federation of Clinical Chemistry (IFCC) as a Reference Laboratory for Pharmacogenetics.

 

Publications

 Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, Mathijssen RH, van Schaik RH. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics. 2013 Jan;14(2):137-49. doi: 10.2217/pgs.12.202.

Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, van Schaik RH. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Res. 2013 May 1;6:331-53. doi: 10.2147/JPR.S42040. Print 2013.

de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, Eskens FA, Wiemer EA, Verweij J, Mathijssen RH,  van Schaik RH. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res. 2013 May 2. [Epub ahead of print]

Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther. 2011 May;89(5):662-73. 

van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME,  Seynaeve C, Lindemans J, Wesseling J, Van `t Veer LJ, Span PN, van Laarhoven H, Sleijfer S, Foekens JA, Linn SC, Berns EM. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics. 2011 Aug;12(8):1137-46. 

 

The Society